ArticleInternational journal of cancer2008
Prostate-derived Ets transcription factor as a favorable prognostic marker in ovarian cancer patients.
Article in International journal of cancer, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 29 citations in OpenAlex.
- SPDEF suppresses head and neck squamous cell carcinoma progression by transcriptionally activating NR4A1.International journal of oral science · 2021Article
- Upregulation of SPDEF is associated with poor prognosis in prostate cancer.Oncology letters · 2019Article
- ELF3, ELF5, EHF and SPDEF Transcription Factors in Tissue Homeostasis and Cancer.Molecules (Basel, Switzerland) · 2018Review
- Gene signature driving invasive mucinous adenocarcinoma of the lung.EMBO molecular medicine · 2017Article
- Signatures of prostate-derived Ets factor (PDEF) in cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Review
- Article
- SPDEF inhibits prostate carcinogenesis by disrupting a positive feedback loop in regulation of the Foxm1 oncogene.PLoS genetics · 2014Article
- PDEF promotes luminal differentiation and acts as a survival factor for ER-positive breast cancer cells.Cancer cell · 2013Article
- SPDEF functions as a colorectal tumor suppressor by inhibiting β-catenin activity.Gastroenterology · 2013Article
- AZGP1 and SPDEF mRNA expression differentiates breast carcinoma from ovarian serous carcinoma.Virchows Archiv : an international journal of pathology · 2013Article
- The transcription factor SPDEF suppresses prostate tumor metastasis.The Journal of biological chemistry · 2012Article
- Mechanisms and functional consequences of PDEF protein expression loss during prostate cancer progression.The Prostate · 2011Article
- Prostate-derived Ets transcription factor (PDEF) is a potential prognostic marker in patients with prostate cancer.The Prostate · 2011Article
- Prostate-Derived ETS Factor Regulates Epithelial-to-Mesenchymal Transition through Both SLUG-Dependent and Independent Mechanisms.Genes & cancer · 2011Article
- Requirement of the epithelium-specific Ets transcription factor Spdef for mucous gland cell function in the gastric antrum.The Journal of biological chemistry · 2010Article
- Loss of PDEF, a prostate-derived Ets factor is associated with aggressive phenotype of prostate cancer: regulation of MMP 9 by PDEF.Molecular cancer · 2010Article
- Generation of a novel transgenic mouse model for bioluminescent monitoring of survivin gene activity in vivo at various pathophysiological processes: survivin expression overlaps with stem cell markers.The American journal of pathology · 2010Article
- Article
- PDEF is a negative regulator of colon cancer cell growth and migration.Journal of cellular biochemistry · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
We have previously shown that ovarian tumors express prostate-derived Ets transcription factor (PDEF). However, the precise role of PDEF in the prognosis of ovarian cancer is unknown. In our study, we report for the first time that expression of PDEF in tumor lesions of patients with ovarian cancer is associated with favorable prognosis. Evaluation of samples from 40 patients with ovarian cancer showed that early stage (IA) and borderline (IIB, III) ovarian tumors expressed higher levels of PDEF mRNA and protein and lower levels of survivin compared to late stage ovarian tumors (IIIC and IV, p < 0.05). Normal ovarian tissues expressed the highest levels of PDEF mRNA and protein when compared to tumor tissues (p < 0.05). A Log-Rank test showed that overall survival of patients with PDEF-positive and survivin-negative ovarian tumors was significantly longer than those with PDEF-negative and survivin-positive tumors (p < 0.01). Forced expression of PDEF in PDEF-negative ovarian tumor cells inhibited tumor cell growth, induced apoptosis, downregulated survivin expression and its promoter activity. Furthermore, treatment of ovarian cancer cells with vitamin D or a selenium compound resulted in re-expression of PDEF, downregulation of survivin, induction of apoptosis and inhibition of tumor cell growth when compared to untreated controls (p < 0.05). Together, these observations showed an inverse correlation between PDEF and survivin expression and suggested that increased PDEF expression along with reduced survivin was associated with prolonged survival of patients with ovarian cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.